Multicenter, Open-Label, Randomized Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT).

The article discusses a study on the efficacy and safety of nipocalimab in pregnancies at risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT), conducted by Janssen Research & Development, LLC, and published in Clinical Trials Week on August 22, 2024. Topics include the study design, primary and secondary outcome measures, and the intervention methods, comparing nipocalimab and intravenous immunoglobulin (IVIG) for managing FNAIT.